Ars Technica has been separating the signal from the noise for over 25 years. With our unique combination of technical savvy and wide-ranging interest in the technological arts and sciences, Ars is ...

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic ...

The younger Art Spiegelman addresses that point. Let's watch this first clip. -Instead of a ritualized story told over and over again, there's such a thing as finding new stories and finding ...

In a report released yesterday, Joshua Schimmer from Cantor Fitzgerald maintained a Buy rating on Aardvark Therapeutics, Inc. (AARD – Research Report), with a price target of $50.00. The company ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...